Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer
- Agreement expands upon Arcus’s industry-leading portfolio of clinical-stage molecules in the adenosine axis -…